Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 156
- Primary Endpoint
- Change in lung cancer related symptoms (LCSS questionnaire)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients, \>/= 18 years of age
- •Histologically or cytologically confirmed non-small cell lung cancer
- •Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab
Exclusion Criteria
- •Contraindications to the use of platinum-based chemotherapy
Outcomes
Primary Outcomes
Change in lung cancer related symptoms (LCSS questionnaire)
Time Frame: up to approximately 6 months (4-6 cycles of chemotherapy)
Correlation of lung cancer related symptoms and disease control rate (complete response, partial response, stable disease according to RECIST criteria)
Time Frame: approximately 2 years
Secondary Outcomes
- Frequency/severity of lung cancer related symptoms (LCSS questionnaire)(approximately 2 years)